Skip to main
REPL

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group Inc has significantly increased the probability of approval for its RP1 + Opdivo treatment in anti-PD1 failed melanoma patients to 85%, reflecting strong confidence in its clinical efficacy. The favorable safety profile of RP1 + Opdivo, indicated by a low 12.8% incidence of Grade 3 or higher treatment-related adverse events, supports its potential market acceptance. The positive IGNYTE trial results further bolster the company's outlook, suggesting robust performance compared to existing therapies in a challenging treatment landscape.

Bears say

Replimune Group Inc faces multiple critical challenges that negatively impact its stock outlook, primarily centered on the efficacy and safety data of its leading candidate, RP1, which is under scrutiny following a negative FDA assessment. The FDA's complete response letter (CRL) highlighted significant concerns regarding the adequacy of the IGNYTE trial, including issues with trial control, population heterogeneity, and insufficient evidence for proposed survival benefits, casting doubt on the regulatory approval and market potential of RP1. Furthermore, the company may confront medium- to long-term dilution risks, emphasizing existing uncertainties surrounding future funding and the viability of its early-stage oncolytic virus pipeline.

REPL has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Buy based on their latest research and market trends.

According to 8 analysts, REPL has a Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.